AR and prostate carcinoma: The initiation of ADT marks the beginning of treatment for castration-naive prostate cancer (CNPC) [18], with the addition of an androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration naive prostate cancer (mCNPC).